These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 35157542)

  • 1. Clinical development and approval of COVID-19 vaccines.
    Kalinke U; Barouch DH; Rizzi R; Lagkadinou E; Türeci Ö; Pather S; Neels P
    Expert Rev Vaccines; 2022 May; 21(5):609-619. PubMed ID: 35157542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 and vaccination: myths vs science.
    Chavda VP; Chen Y; Dave J; Chen ZS; Chauhan SC; Yallapu MM; Uversky VN; Bezbaruah R; Patel S; Apostolopoulos V
    Expert Rev Vaccines; 2022 Nov; 21(11):1603-1620. PubMed ID: 35980281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The race for a COVID-19 vaccine: where are we up to?
    Hossain MK; Hassanzadeganroudsari M; Feehan J; Apostolopoulos V
    Expert Rev Vaccines; 2022 Mar; 21(3):355-376. PubMed ID: 34937492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility.
    Eccleston-Turner M; Upton H
    Milbank Q; 2021 Jun; 99(2):426-449. PubMed ID: 33650737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 Vaccine Diplomacy and Equitable Access to Vaccines Amid Ongoing Pandemic.
    Sharun K; Dhama K
    Arch Med Res; 2021 Oct; 52(7):761-763. PubMed ID: 33941393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to accelerate the supply of vaccines to all populations worldwide? Part I: Initial industry lessons learned and practical overarching proposals leveraging the COVID-19 situation.
    McGoldrick M; Gastineau T; Wilkinson D; Campa C; Clercq N; Mallia-Milanes A; Germay O; Krishnan J; Van Ooij M; Thien MP; Mlynarczyk PJ; Saltus E; Juvin P; Clenet D; Basso A; Dellepiane N; Pagliusi S; de Moraes Stávale MC; Sivaramakrishnan VH; Desai S
    Vaccine; 2022 Feb; 40(9):1215-1222. PubMed ID: 35180993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors, enablers and challenges for COVID-19 vaccine development.
    Excler JL; Saville M; Privor-Dumm L; Gilbert S; Hotez PJ; Thompson D; Abdool-Karim S; Kim JH
    BMJ Glob Health; 2023 Jun; 8(6):. PubMed ID: 37277195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Vaccines: Where Are We Now?
    Flanagan KL; MacIntyre CR; McIntyre PB; Nelson MR
    J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3535-3543. PubMed ID: 34400116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global pandemic preparedness: learning from the COVID-19 vaccine development and distribution.
    Agampodi S; Mogeni OD; Chandler R; Pansuriya M; Kim JH; Excler JL
    Expert Rev Vaccines; 2024; 23(1):761-772. PubMed ID: 39167221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy.
    Parums DV
    Med Sci Monit; 2021 Sep; 27():e934625. PubMed ID: 34483336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed Access to COVID-19 Vaccines: A Perspective on Low-income Countries in Africa.
    Hassan MA; Aliyu S
    Int J Health Serv; 2022 Jul; 52(3):323-329. PubMed ID: 35469499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is COVID-19 vaccine inequality undermining the recovery from the COVID-19 pandemic?
    Suárez-Álvarez A; López-Menéndez AJ
    J Glob Health; 2022 May; 12():05020. PubMed ID: 35604879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the vaccine development for the prophylaxis of SARS Covid-19.
    Kumar V; Kumar S; Sharma PC
    Int Immunopharmacol; 2022 Oct; 111():109175. PubMed ID: 35994853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine safety - is the SARS-CoV-2 vaccine any different?
    Tau N; Yahav D; Shepshelovich D
    Hum Vaccin Immunother; 2021 May; 17(5):1322-1325. PubMed ID: 33270474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons learned from the SARS-CoV-2 pandemic; from nucleic acid nanomedicines, to clinical trials, herd immunity, and the vaccination divide.
    Hussain H; Ganesh A; Milane L; Amiji M
    Expert Opin Drug Deliv; 2023 Apr; 20(4):489-506. PubMed ID: 36890642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.